Results 71 to 80 of about 91,755 (270)

Efficacy and Safety of Durvalumab and Tremelimumab in Metastatic Non‐Small Cell Lung Cancer: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials

open access: yesChronic Diseases and Translational Medicine, EarlyView.
PRISMA 2020 flow diagram of included studies. ABSTRACT Purpose Immune checkpoint inhibitors have transformed treatment strategies for metastatic non‐small cell lung cancer (mNSCLC). This study aimed to assess the efficacy and safety of durvalumab combined with tremelimumab compared with those of standard chemotherapy, particularly in patients with low ...
Ikhwan Rinaldi   +2 more
wiley   +1 more source

Recurrent gastric cancer sustaining a partial response after the nivolumab discontinuation because of immune-related adverse events: a case report

open access: yesSurgical Case Reports, 2020
Background The prognosis of patients with recurrent gastric cancer is poor despite chemotherapy being clinically recommended as the first therapeutic strategy.
Takaaki Arigami   +10 more
doaj   +1 more source

Bilateral Sensorineural Hearing Loss Associated With Nivolumab Therapy for Stage IV Malignant Melanoma

open access: yesEar, Nose & Throat Journal, 2021
Objectives: Present the case of a 67-year-old male with stage IV malignant melanoma who presented with uveitis and sensorineural hearing loss (SNHL) while on nivolumab and review the literature for likely etiologies.
Alex J. F. Tampio MD   +3 more
doaj   +1 more source

Time‐Dependent Bias and Prognostic Confounding in Exposure–Response Analysis of Targeted Therapies: Lessons from Sunitinib in Metastatic Renal Cancer

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Exposure–response (E–R) analyses of sunitinib in metastatic renal cell carcinoma (mRCC) have supported concentration‐guided dose escalation. However, such analyses may be biased when exposure metrics incorporate post‐baseline dose modifications, time‐varying apparent clearance, or baseline factors that influence both pharmacokinetics and clinical ...
Han Liu, Lena E. Friberg
wiley   +1 more source

A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors

open access: yesJournal for ImmunoTherapy of Cancer, 2018
Background Escalating healthcare costs are necessitating the practice of value-based oncology. It is crucial to critically evaluate the economic impact of influential but expensive therapies such as immune checkpoint inhibitors (ICIs).
Vivek Verma   +6 more
doaj   +1 more source

Genital lichen sclerosus after nivolumab [PDF]

open access: yes, 2020
We report a patient with metastatic melanoma undergoing treatment with nivolumab who developed genital lichen sclerosus.
Soda, Giuseppe   +6 more
core   +1 more source

Conservative management of nivolumab-induced pericardial effusion: a case report and review of literature

open access: yesExperimental Hematology & Oncology, 2018
Background Nivolumab is an immune checkpoint inhibitor targeting programmed death-1 protein and has been approved for the treatment of multiple advanced malignancies.
Shagufta Shaheen   +3 more
doaj   +1 more source

A Case Report of Steroid Responsive Nivolumab-Induced Encephalitis

open access: yes, 2017
Nivolumab (Opdivo) approval for the treatment of non-small cell lung cancer (NSCLC) prompts recognition of its future use in various cancers. Although rare, occurring in 1% to 3% of treated cases, nivolumab along with other immune checkpoint inhibitors ...
Sowmya Nanjappa   +3 more
core   +1 more source

Treatment Patterns and Survival Outcomes of Head and Neck Merkel Cell Carcinoma: An Age‐Stratified Analysis

open access: yesHead &Neck, EarlyView.
ABSTRACT Background H&N Merkel cell carcinoma (MCC) mainly affects elderly patients, yet age‐stratified treatment patterns and outcomes data are scarce. Methods We analyzed 88 consecutive H&N MCC patients (2000–2022) by age (< 75 vs. ≥ 75 years). OS was estimated by Kaplan–Meier analysis and MCC‐specific death with competing‐risks methods (cause ...
Igor Vainer   +3 more
wiley   +1 more source

Risk of immune-related adverse events associated with ipilimumab-plus-nivolumab and nivolumab therapy in cancer patients

open access: yesTherapeutics and Clinical Risk Management, 2019
Shi Zhou,* Samrat Khanal,* Haijun Zhang Department of Oncology, Zhongda Hospital, Medical School of Southeast University, Nanjing, Jiangsu, People’s Republic of China *These authors contributed equally to this work Purpose: The aim of this study
Zhou S, Khanal S, Zhang H
doaj  

Home - About - Disclaimer - Privacy